Lapatinib Plus Trastuzumab Was Not Superior to Trastuzumab Alone or Trastuzumab Followed by Lapatinib for Improved DFS in Women with HER2+ Breast Cancer is a research paper published in MD Conference Express (2014). On theSindex it has a DataRank of 0.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
FWCI
0.00
Citation Percentile
0.2%
Fields of Study
Keywords
Sustainable Development Goals